Archive for the ‘Treatment’ Category

Methylene Blue for Lyme & Bartonella (Also COVID)

https://www.treatlyme.net/guide/methylene-blue-for-lyme-and-bartonella  Video Here

Methylene Blue for Lyme and Bartonella: The Ins and Outs

By Dr. Marty Ross

Methylene Blue for Lyme and Bartonella Persisters

The Ins and Outs of Methylene Blue

Methylene blue is a repurposed drug used to treat persister Lyme (Borrelia) and Bartonella. There is also lab evidence showing it treats growing Bartonella. It likely kills growing Lyme too. While methylene blue may treat growing germs, the main reason to use it in Lyme or Bartonella infectious is to treat persisters.

In this video article, Marty Ross, MD discusses the ins and outs, including risks factors, of using methylene blue. Below the video, you can find sample antibiotic protocols for Lyme and Bartonella that include methylene blue.

Notice-How to Use This Article

Be aware, most of the important information in this article is in the video in the top link

(See link for article and video)

______________

**Comment**

Methylene blue, like DMSO and ozone are more like therapeutic principles than drugs and work for many disease processes including COVID, yet mainstream medicine & media is remarkably silent because these safe, cheap, effective alternatives interfere with their conflicts of interest.  The same can be said for ivermectin and HCQ/zinc, as well as long-term antibiotics for Lyme/MSIDS sufferers who continue to have symptoms.

For more:

For more on Bartonella treatment:

For more on MB for COVID:

  • https://www.nature.com/articles/s41598-021-92481-9  MB displays broad-spectrum virucidal activity in the presence of UV light and inactivates various viruses in blood products prior to transfusions.  It’s validated for treating methemoglobinemia and malaria.  Our findings reveal that methylene blue displays virucidal preventive or therapeutic activity against influenza virus H1N1 and SARS-CoV-2 at low micromolar concentrations and in the absence of UV-activation. We also confirm that MB antiviral activity is based on several mechanisms of action as the extent of genomic RNA degradation is higher in presence of light and after long exposure. Our work supports the interest of testing methylene blue in clinical studies to confirm a preventive and/or therapeutic efficacy against both influenza virus H1N1 and SARS-CoV-2 infections.
  • https://biomedres.us/pdfs/BJSTR.MS.ID.006723.pdfSeven outpatients with confirmed cases of severe COVID-19 received oral MB (the reduced form: 1mg/kg T.I.D. for 2-days, followed by 1mg/kg B.I.D. for the next 12 days) along with standard care. Outpatients recovered completely.  Considering all properties of MB such as anti-viral, antibiotic, anticoagulant, immunomodulatory, antioxidants, anti-hypoxemia, and anti-respiratory; it could be applied as an adjunct therapy along with standard care protocols in the clinical management of COVID-19 outpatients. MB is a cheap and FDA-approved drug for methemoglobinemia.
  • https://www.news-medical.net/news/20220325/Study-finds-methylene-blue-is-a-low-micromolar-inhibitor-of-the-the-SARS-CoV-2-spike-protein-and-ACE2-interaction.aspx  Authors of this study revealed that MeBlu is a low‐micromolar inhibitor of the PPI that suppresses interaction between the S protein of SARS-CoV-2 and its cognate receptor ACE2. The dye was also found to be effective against the Delta variant and to suppress virus replication in Vero E6 cells. Scientists believe that MeBlu could be used as an inexpensive drug for the treatment of SARS-CoV-2 infection.
  • https://clinicaltrials.gov/ct2/show/NCT04933864  Since methylene blue can work as a photosensitizer, photodynamic therapy as an antiviral treatment has great potential in the treatment of COVID-19. (The study is ongoing so results are yet to be known)
  • https://pubmed.ncbi.nlm.nih.gov/34019535/  The addition of MB to the treatment protocols significantly improved SpO2 and respiratory distress in COVID-19 patients, which resulted in decreased hospital stay and mortality.
  • https://www.frontiersin.org/articles/10.3389/fphar.2020.600372/full  Screening of our organic dye-based library identified MeBlu as a low-micromolar inhibitor of the interaction between SARS-CoV-2 spike protein and its cognate receptor ACE2, a PPI that is the first critical step initiating the viral entry of this coronavirus. While MeBlu shows strong polypharmacology and might be a somewhat promiscuous PPI inhibitor, its ability to inhibit this PPI could contribute to the antiviral activity of MeBlu against SARS-CoV-2 even in the absence of light making this inexpensive and widely available drug potentially useful in the prevention and treatment of COVID-19 as an oral or inhaled medication.
  • https://www.sciencedirect.com/science/article/pii/S0753332221008064  Currently, the treatment of COVID-19 involves use of antiviral and anti-cytokine drugs. However, both the drugs have low efficacy because they cannot inhibit the production of free radicals and cytokines at the same time. Recently, some researchers have reported the use of methylene blue(MB) in COVID-19 management. MB has been used since a long time as a therapeutic agent, and has been approved by the US FDA for the treatment of other diseases. The additional advantage of MB is its low cost. MB is a safe drug when used in the dose of < 2 mg/kg. In this review, the applicability of MB in COVID-19 and its mechanistic aspects have been explored and compiled. The clinical studies have been explained in great detail. Thus, the potential of MB in the management of COVID-19 has been examined.  The results are satisfactory and provide a ray of hope in this direction. Thus, MB can be termed as a “rescue magic bullet” for COVID-19 treatment. However, for MB administration, meticulous consideration of the dosage is necessary to prevent any untoward effects. MB can be administered thrice orally at a dose of 2–3 mg/kg per day for 7–10 days in newly infected COVID-19 patients. However, this needs to be further studied, and finding the optimal dosage should be the objective of clinical study [43]. The use of MB in novel dosage forms like an anti-COVID mouthwash may also be beneficial [77].  **Warning** MB can interact with antidepressants (selective serotonin reuptake inhibitors and MAO inhibitors) to cause sever toxicity of serotonin.  It also has been found to interact with with dapsoneto form hydroxylamine, which oxidizes hemoglobin and may cause hemolysis [84]. Also, MB is contraindicated in patients with severe renal insufficiency. The use of MB in patients with G6PD deficiency can be detrimental, as it may cause severe hemolysis [53]. In such cases, the use of vitamin B12 and ascorbic acid has proven to be beneficial [85], [86], [87]. Additionally, concomitant use of NSAIDs may block the bradykinin activity pathways. Thus, NSAIDs may add benefit to MB therapy in COVID-19 [64], [88].

Category:

Bartonella, Lyme, Treatment

LDN For Lyme

https://www.treatlyme.net/guide/low-dose-naltexone-lyme-disease

Updated: 3/21/23

About Low-Dose Naltrexone for Lyme

Low-dose naltrexone (LDN) is very useful in Lyme disease. This low-cost medicine can

  • improve nerve, muscle, and inflammation pain,
  • decrease autoimmune illness triggered by Lyme,
  • improve mast cell activation symptoms,
  • lower cytokine inflammation, and
  • improve immune system function by increasing TRegs to balance Th1 and Th2.

In this article, I review the science and method for how LDN works. I describe how to use it in Lyme disease, and I review potential side effects.  (See link for article & video)

________________

For more:

Category:

Inflammation, Lyme, Pain Management, Sleep, Supplements, Treatment

Fatal Case of Heartland Virus

https://danielcameronmd.com/fatal-case-of-heartland-virus/

FATAL CASE OF HEARTLAND VIRUS

fatal-heartland-virus

The Heartland virus (HRTV) is an emerging tick-borne illness which can be acquired through the bite of an infected Lone Star tick. The virus was first reported in 2009 in Missouri. Since then, it has spread to other states including Kansas, Oklahoma, Arkansas, Tennessee, Kentucky, Indiana, Illinois, Iowa, Georgia, Pennsylvania, New York, and North Carolina, according to the Centers for Disease Control and Prevention (CDC).

By 

Now, investigators have identified the Heartland virus in the Maryland and Virginia region – an area where the virus is not widely recognized.

In their article “Fatal Case of Heartland Virus Disease Acquired in the Mid-Atlantic Region, United States,”¹ Liu and colleagues describe the fatal case of a man in his 60’s who acquired the Heartland virus in either Maryland or Virginia.

The man was admitted to the hospital in November 2021 with a fever, diarrhea, dyspnea, myalgias, and malaise which had been ongoing for 5 days. He had a history of a splenectomy, hypertension, remote trauma, coronary artery disease, and hypertension.

The patient did not recall a tick bite and did not have an erythema migrans rash.

“The range of [Heartland virus] could be expanding in the United States.”

“An arboviral disease was the leading diagnostic consideration, but limited availability of commercial diagnostic testing for tickborne diseases delayed diagnosis,” wrote Liu et al.

The man was treated clinically for a tick-borne infection with doxycycline.

“Two days later, on day 7 after symptom onset, the patient returned to the emergency department with confusion, an unsteady gait, and new fecal and urinary incontinence,” according to the authors.

He subsequently developed encephalopathy, low sodium, abnormal liver function tests, and fatigue.

“He had acute respiratory failure, renal failure, and a cardiac arrest. He was transitioned to comfort care and died on day 13 after symptom onset,” wrote Liu et al.

An autopsy revealed that the heart, spleen, kidney, and liver samples were positive for Heartland virus.

The Virginia Department of Health conducted a drag of the man’s property and found 193 Lone Star ticks. However, none of the ticks contained HRTV.

Tick-borne diseases identified by the CDC, as of 2/26/23.²

  • Anaplasmosis
  • Babesiosis
  • Borrelia mayonii
  • Borrelia miyamotoi
  • Bourbon virus
  • Colorado tick fever
  • Ehrlichiosis
  • Heartland virus
  • Lyme disease
  • Powassan disease
  • Rocky Mountain spotted fever (RMSF)
  • STARI (Southern tick-associated rash illness)
  • Tick-borne relapsing fever (TBRF)
  • Tularemia
  • 364D rickettsiosis (Rickettsia phillipi, proposed)
Related Articles:

10 cases of Heartland virus reviewed

References:
  1. Liu S, Kannan S, Meeks M, et al. Fatal Case of Heartland Virus Disease Acquired in the Mid-Atlantic Region, United States. Emerg Infect Dis. Feb 23 2023;29(5)doi:10.3201/eid2905.221488
  2. Diseases Transmitted by Ticks. Centers for Disease Control and Prevention. https://www.cdc.gov/ticks/diseases/index.html Last accessed 2/26/23.

For more:

Category:

research, Testing, Ticks, Treatment, Viruses

Dr. Steven Phillips on Chronic Inflammation

http://  Approx. 1 Hour

March 25, 2023

Dr. Steven Phillips Discusses Chronic Inflammation

Dr. Steven Phillips discusses chronic inflammation and its management, especially in the context of long COVID and “vaccine” injuries.

Dr. Steven Phillips’ bio: Steven Phillips, MD is a well published, Yale-trained physician, researcher, and bestselling author, whose focus of medical practice and research is that chronic and autoimmune illness can be caused by underlying infections.

Dr. Phillips’ substack: https://zerospin.substack.com/

Amazon.com: Chronic: The Hidden Cause of the Autoimmune Pandemic and How to Get Healthy Again (Audible Audio Edition): Steven Phillips MD, Dana Parish, Teri Schnaubelt, Thomas Allen, Brilliance Audio: Books https://www.amazon.com/Chronic-Hidden…

http://

Dr. Steven Phillips Discusses Chronic Diseases (Lyme & COVID)

Steven Phillips, M.D. is a renowned Yale-trained physician, author, international lecturer, and media go-to expert. Well-published in the medical literature, he has treated over 20,000 patients with complex, chronic illness from nearly 20 countries. Phillips experienced firsthand the nightmare of an undiagnosed, serious infection after nearly dying from his own “mystery illness,” and having to save his own life when 25 doctors could not.

Here are the questions we will ask Dr. Phillips:

  • What is Lyme+?
  • What is your own story of Lyme?
  • You say that many infections are categorized as Lyme, how do we separate them
  • Are there good tests for Lyme+?
  • Is it treatable?
  • Is there hope for hundreds of thousands of patients of Lyme+?
  • How can an infection cause autoimmune disorders?
  • What is the role of Th1 and Th2 system in this context?
  • Why does it become chronic?
  • Do I have a vector borne infection?
  • We are seeing the same issue with COVID – Is COVID becoming similarly mismanaged?
  • How should patients approach their chronic Lyme+?
  • Is there hope?
  • How do people get help from you?
  • Do you train other doctors with your protocol?
  • Do they reach out to you?
  • On page 63 you write: Despite my repeatedly negative brucellosis testing at U.S. labs, I shared with my Lyme doctor my ideas for an aggressive combination antibiotic treatment against this infection. Nothing else was working, so my doctor agreed to the plan, and by the second month of treatment I started to improve.
  • Tell us about Jarish-Hexheimer reaction
  • Before we go, tell us how can people find you?

For more:

Hospital payments include:

  • A “free” required PCR test in the Emergency Room or upon admission for every patient, with government-paid fee to hospital.  This test, like Lyme testing, is an utter farce.
  • Added bonus payment for each positive COVID-19 diagnosis, based on a worthless test.
  • Another bonus for a COVID-19 admission to the hospital, based on a worthless test.
  • A 20% “boost” bonus payment from Medicare on the entire hospital bill for use of remdesivir instead of medicines such as Ivermectin, all based on a worthless test.
  • Another and larger bonus payment to the hospital if a COVID-19 patient is mechanically ventilated, all based on a worthless test.
  • More money to the hospital if cause of death is listed as COVID-19, even if patient did not die directly of COVID-19, which is all based on a worthless test.
  • A COVID-19 diagnosis also provides extra payments to coroners, all based on a worthless test.

CMS implemented “value-based” payment programs that track data such as how many workers at a healthcare facility receive a COVID-19 “vaccine.” Now we see why many hospitals implemented COVID-19 vaccine mandates. They are paid more.  Source

For those paying attention, COVID is a replay of Lyme and many of the same tactics have been deployed.

Category:

Activism, Inflammation, Lyme, Treatment, Viruses

IV Antibiotics Helpful For PTLDS

https://danielcameronmd.com/intravenous-antibiotics-helpful-for-ptlds/

INTRAVENOUS ANTIBIOTICS HELPFUL FOR PTLDS

antibiotics-ptlds

Post Treatment Lyme Disease Syndrome (PTLDS) can develop in patients even after receiving antibiotic treatment for Lyme disease. Although the exact cause of PTLDS is unknown, it could be due to a persistent infection. PTLDS is characterized by fatigue, pain and cognitive difficulties.

By 

In their study “Efficacy and safety of antibiotic therapy for post-Lyme disease? A systematic review and network meta-analysis,” Zhang and colleagues described a meta-analysis review of four Randomized Clinical Trials (RCT) addressing Post-Treatment Lyme Disease Syndrome.¹

The four randomized controlled trials included 485 subjects who met the following inclusion criteria:

  • Randomized controlled trials
  • Patients with Post-Lyme Disease Syndrome which has persisted for at least 6 months after treatment of the initial infection and who tested positive by IgG Western blot
  • Patients aged 18 years and above
  • Number of cases providing valid data to measure outcomes
  • Studies that the control group used placebo, while the observation group took the antibiotic

Their meta-analysis showed that ceftriaxone had better results than placebo on FSS. “FSS-11 is the most widely used scale to measure the fatigue severity of the subjects,” wrote Zhang et al.

“Ceftriaxone treatment may be the best choice for antibiotic treatment of PTLD, which provides useful guidance for antibiotic treatment of PTLD in the future.”

The systemic meta-analysis concluded that intravenous ceftriaxone may be the best choice for treating Post-Treatment Lyme Disease Syndrome.

An NIH-sponsored clinical trial demonstrated that intravenous ceftriaxone therapy improved patients’ cognitive function in the short term, according to Fallon.² There were no trials addressing pain.

The authors were not able to show significant gains in the Beck Depression Inventory (BDI), Mental Health Scale and Physical Functioning Scales. Neither were they able to show significant gains with oral doxycycline.

Zhang et al. acknowledged several limitations to their study. “The number of RCTs is small; The duration and dose of treatment in these RCTs are not uniform; The follow-up time of various RCTs is different to some extent.”

Author’s Note: I have been reluctant to recognize the term PTLDS until there is a reliable test to exclude a persistent infection. This systemic meta-analysis validated my concerns that PTLDS may be the result of a persistent infection.

Related Articles:

Podcast: Post-Treatment Lyme Disease Syndrome Cases

4 Distinct Post-Treatment Lyme Disease Syndromes?

Number of Post-Treatment Lyme Disease Syndrome cases expected to soar

References:
  1. Zhang X, Jiang Y, Chen Y, et al. Efficacy and safety of antibiotic therapy for post-Lyme disease? A systematic review and network meta-analysis. BMC Infect Dis. Jan 12 2023;23(1):22. doi:10.1186/s12879-023-07989-4
  2. Fallon BA, Keilp JG, Corbera KM, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. Mar 25 2008;70(13):992-1003. doi:10.1212/01.WNL.0000284604.61160.2d

________________

For more:

Please note that the FDA’s continued attack on supplements and medications it deems a threat could very well impact Lyme/MSIDS patients.

Category:

Activism, Lyme, research, Treatment